Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Latest Press Releases
What crisis? Biopharma rallies strongly after COVID-19 shock: New report from Evaluate Vantage
“Pharma, Biotech and Medtech Half-Year Review 2020” analyses the market performance and deal landscape for the first half of 2020, focusing on the impact of COVID-19
Global demand for innovation prevails over challenges of COVID-19: new report from Evaluate Ltd.
The impact of COVID-19 has so far wiped $7.85bn off forecasts for biopharma sales in 2020, with the top 15 companies bearing 60% of that loss, according to the…
Virtual partnering event launched to accelerate partnerships in the life sciences industry to fight against COVID-19
COVID-19 Virtual Partnering is a unique and free-to-attend virtual event taking place on 20 April – 06 May. The initiative is backed by a consortium of biotech clusters…
Browse the archive
What crisis? Biopharma rallies strongly after COVID-19 shock: New report from Evaluate Vantage
“Pharma, Biotech and Medtech Half-Year Review 2020” analyses the market performance and deal landscape for the first half of 2020, focusing on the impact of COVID-19
Global demand for innovation prevails over challenges of COVID-19: new report from Evaluate Ltd.
The impact of COVID-19 has so far wiped $7.85bn off forecasts for biopharma sales in 2020, with the top 15 companies bearing 60% of that loss, according to the…
Virtual partnering event launched to accelerate partnerships in the life sciences industry to fight against COVID-19
COVID-19 Virtual Partnering is a unique and free-to-attend virtual event taking place on 20 April – 06 May. The initiative is backed by a consortium of biotech clusters…
Evaluate Ltd. acquires Black Swan Analysis, accelerating the growth strategy of the business and further optimising the product portfolio
Evaluate Ltd., the leading provider of commercial intelligence and predictive analytics to the pharmaceutical industry, is delighted to announce today that it has…
Evaluate Vantage 2019 Review: Standout year for pharma, anchored by strong fourth quarter markets and dealmaking
Stock market gains and dealmaking activity in Q4 clinched the biopharma sector’s strong performance in 2019 – a stark reversal of the declines seen in the final months of…
Evaluate Vantage 2020 Preview: Strong sales and product launches set the stage for biopharma growth, but underlying market concerns exist
Oncology dominates the growth outlook for pharma; four of the eight drugs expected to add $1bn or more in new sales next year are for cancer, according to the Evaluate…
Evaluate Ltd. appoints Martyn Hindley as Chief Financial Officer
Evaluate Ltd., the leading provider of commercial data to the life sciences industry, is pleased to announce the appointment of Martyn Hindley as Chief Financial Officer,…
Evaluate Ltd. transforms pharma R&D risk assessment with launch of Product Specific PTRS
Breakthrough offering combines the power of machine learning with the transparency of Evaluate’s renowned analytical approach for the most accurate analysis of drug…
Evaluate Vantage Half-Year Review 2019: Pharma and medtech mega-deals mask drop in M&A activity
The report, published today, analyses stock and market performance, M&A and the financing landscape during the first half of 2019
Innovation and unmet need drive prescription drug sales to $1.18tr by 2024: new report from Evaluate Ltd
“EvaluatePharma® World Preview 2019, Outlook to 2024” explores growth drivers, growth brakes and top industry performers.
